Vor Biopharma (VOR) Depreciation & Amortization (CF) (2020 - 2026)
Vor Biopharma (VOR) posted quarterly Depreciation & Amortization (CF) of $28000.0 for Q1 2026, down 96.5% year-over-year from $800000.0 in Q1 2025, and down 22.22% quarter-over-quarter from $36000.0 in Q4 2025.
Vor Biopharma (VOR) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Vor Biopharma (VOR) has reported Depreciation & Amortization (CF) for 7 consecutive years, with $28000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 96.5% year-over-year to $28000.0; the TTM figure through Mar 2026 stood at $2.2 million (down 36.29% YoY), while the FY2025 annual figure was $2.9 million, down 17.14% from the prior year.
- Depreciation & Amortization (CF) declined to $28000.0 in Q1 2026 per VOR's latest filing, from $36000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $2.1 million in Q2 2025 and bottomed at $2000.0 in Q3 2025.
- Historically, Depreciation & Amortization (CF) has averaged $739000.0 across 5 years, with a median of $837000.0 in 2023.
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) jumped 200.0% — and 2025, when it sank 99.78%.
- Vor Biopharma's Depreciation & Amortization (CF) stood at $625000.0 in 2022, then jumped by 42.72% to $892000.0 in 2023, then slipped by 10.31% to $800000.0 in 2024, then plunged by 95.5% to $36000.0 in 2025, then decreased by 22.22% to $28000.0 in 2026.
- Business Quant data shows VOR's Depreciation & Amortization (CF) at $28000.0 in Q1 2026, $36000.0 in Q4 2025, and $2000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 40.52 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | Vor Biopharma | 1.36 Bn | 1.36 Bn | - | 36,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 36,000.00 |
| Jun 30, 2026 | 36,000.00 |
| Mar 31, 2026 | 28,000.00 |
| Mar 31, 2026 | 28,000.00 |
| Dec 31, 2025 | 36,000.00 |
| Dec 31, 2025 | 36,000.00 |
| Sep 30, 2025 | 2,000.00 |
| Sep 30, 2025 | 2,000.00 |
| Jun 30, 2025 | 2.10 Mn |
| Jun 30, 2025 | 2.10 Mn |
| Mar 31, 2025 | 800,000.00 |
| Mar 31, 2025 | 800,000.00 |
| Dec 31, 2024 | 800,000.00 |
| Dec 31, 2024 | 800,000.00 |
| Sep 30, 2024 | 900,000.00 |
| Sep 30, 2024 | 900,000.00 |
| Jun 30, 2024 | 900,000.00 |
| Jun 30, 2024 | 900,000.00 |
| Mar 31, 2024 | 943,000.00 |
| Mar 31, 2024 | 943,000.00 |